Know Cancer

forgot password

A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)

Phase 1
18 Years
Open (Enrolling)
Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer

Thank you

Trial Information

A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)

Inclusion Criteria:

- Histologically-confirmed MBC not deemed amenable to curative surgery or curative
radiation therapy

- Tumors are positive for ER, PgR, or both

- Tumors must be negative for HER2 (by FISH, CISH or IHC)

- Female gender and age ≥ 18 years at time of study entry

- Postmenopausal

- Karnofsky Performance Status ≥ 70

- Life expectancy of ≥ 6 months

Exclusion Criteria:

- Subjects who received prior chemotherapy, hormonal therapy, immunotherapy or biologic
therapy for advanced or metastatic disease with the following exceptions:

- Prior adjuvant therapy with an AI and/or tamoxifen is allowed, provided
treatment ended at least 2 weeks prior to the first dose of MEDI-573

- Prior neoadjuvant and/or adjuvant chemotherapy for breast cancer is allowed

- Extensive symptomatic visceral disease including hepatic involvement and pulmonary
lymphangitic spread of tumor, or disease that is considered by the investigator to be
rapidly progressing or life threatening (eg, subjects who are intended for

- Active brain metastases with the exception of subject has been treated and are
asymptomatic and there has been no evidence of CNS progression for at least 4 weeks
of first dose of MEDI-573

- Evidence of ongoing spinal cord compression or leptomeningeal carcinomatosis

- Unresolved toxicities from prior therapy with the exception of alopecia that have not
resolved to ≤ Grade 1 at the time of starting study treatment

- Previous treatment with agents that target the IGF receptor

- History of allergy or reaction attributed to compounds of chemical or biologic
composition similar to those of MEDI-573 or AI

- History of another invasive malignancy within 5 years except for curatively resected
nonmelanoma skin cancer or carcinoma in situ of the cervix

- Poorly controlled diabetes mellitus

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Phase Ib: Safety and tolerability of 2 dose levels of MEDI-573 combined with AI

Outcome Description:

The primary objective of the dose-evaluation phase is to evaluate the safety and tolerability of 3 dose levels of MEDI 573 in combination with an AI in subjects with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative MBC. Specific endpoints: number of subjects with AEs, SAEs, and DLTs.

Outcome Time Frame:

5 months

Safety Issue:


Principal Investigator

Jennifer McDevitt, PharmD, Ph.D.

Investigator Role:

Study Director

Investigator Affiliation:

MedImmune LLC


United States: Food and Drug Administration

Study ID:




Start Date:

June 2011

Completion Date:

August 2015

Related Keywords:

  • Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
  • MEDI-573, breast cancer, metastatic, aromatase inhibitor, anti-IGF
  • Breast Neoplasms



Research Site Mesa, Arizona  
Research Site Anaheim, California  
Research Site Danbury, Connecticut  
Research Site Boca Raton, Florida  
Research Site Albany, Georgia  
Research Site Bangor, Maine  
Research Site Baltimore, Maryland  
Research Site Beverly, Massachusetts  
Research Site Battle Kreek, Michigan  
Research Site Alexandria, Minnesota  
Research Site Grand Island, Nebraska  
Research Site Belleville, New Jersey  
Research Site Albuquerque, New Mexico  
Research Site Albany, New York  
Research Site Akron, Ohio  
Research Site Allentown, Pennsylvania  
Research Site Chattanooga, Tennessee  
Research Site Abilene, Texas  
Research Site Abington, Virginia